Tag: BioNTech

Investors in the Mainz-based biotechnology firm BioNTech received an unexpected financial update, as the company dramatically revised its annual revenue ...

Investor attention is firmly fixed on BioNTech today as the German biopharmaceutical company prepares to release quarterly results that could ...

After an extended period of decline, BioNTech's stock is finally demonstrating positive momentum. The vaccine pioneer recorded gains exceeding 6 ...

Investors in BioNTech are bracing for a pivotal moment as the biotechnology firm prepares to release its quarterly financial results. ...

Investors are preparing for a pivotal week for BioNTech shares, with the company's third-quarter 2025 financial report scheduled for release ...

German biotechnology firm BioNTech has initiated a significant strategic shift with its $1.25 billion acquisition of competitor CureVac, marking a ...

As markets await forthcoming quarterly results, BioNTech is signaling its strategic direction beyond the pandemic era. The German biopharmaceutical company ...

In a decisive move for Germany's biotechnology sector, the Federal Cartel Office has granted unconditional approval for BioNTech's proposed acquisition ...

BioNTech has reached a significant milestone in its return to cancer research, announcing positive results from a pivotal Phase 3 ...

BioNTech's corporate narrative is expanding beyond its Mainz headquarters, with Africa emerging as a crucial theater for its future operations. ...